Clinical trial
An Open Label Study of Oral Enzastaurin in Participants With Cancer
NCT00309140 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00309140 |
|---|---|
| Title | An Open Label Study of Oral Enzastaurin in Participants With Cancer |
| Official title | An Open-Label Study of Oral Enzastaurin HCl in Patients With Advanced or Metastatic Malignancies |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Cancer |
| Intervention type | Drug |
| Interventions | enzastaurin |
| Enrollment | 23 |
| Start date | Mar 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Mar 31, 2006 |
| Last update posted | Jun 26, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: